Cardiovascular Diseases Clinical Trial
Official title:
Measures of Postprandial Lipoproteins Are Not Associated With Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus
To better understand the excess cardiovascular disease associated with diabetes mellitus.
BACKGROUND:
Diabetes mellitus is associated with a 2-4 fold increase in risk for atherosclerotic
cardiovascular disease. Atherosclerotic cardiovascular disease, particularly coronary artery
disease, is the leading cause of death in diabetics. The study was a subproject within a
program project grant, with Henry Ginsberg as principal investigator. The program project
was part of an institute-initiated study on The Etiology of Excess Cardiovascular Disease in
Diabetes Mellitus. The initiative originated after discussions between NHLBI and the
Juvenile Diabetes Foundation International (JDFI). The Request for Applications (RFA) was
originally issued in October 1994 and resulted in the award of one grant The RFA was
reissued in December 1995 and resulted in the awarding of five program project grants, the
one under discussion among them.
DESIGN NARRATIVE:
The study, subproject 3 within a program project grant, was entitled Atherogenic
Triglyceride Rich Lipoproteins in Diabetes. The subproject examined the atherogenicity of
hypertriglyceridemia in subjects with non-insulin dependent diabetes mellitus (NIDDM).
Subproject 3 tested hypotheses concerning the impact of the size and number of
triglyceride-rich lipoproteins (TGRL) on risk for atherosclerotic cardiovascular disease
(ASCVD) in several human populations. A case-control study of diabetics with or without
coronary artery disease determined if TGRL size and number differed between the groups. In
this study, Whites, Blacks and Hispanics with documented coronary artery disease or with
less than 50 percent coronary stenosis by angiography were recruited. The hypothesis was
tested that increased apoB in small TGRL was associated with coronary artery disease.
Fasting and postprandial blood samples were obtained for measurement of TGRL apoB level,
TGRL TG:apoB ratio, the amount of apoB in apoE-rich TGRL, and retinyl palmitate clearance.
Allelic differences in the apoB, apoE, LPL, and apoCIII genes were examined for effects on
the size and number of TGRL: specific hypotheses were tested regarding the impact of these
alleles.
TGRL size and number were also compared in diabetics with and without carotid
atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) study, in Sioux and Pima
Indian tribes that differed in ASCVD rates, and in Blacks, Whites and Hispanics with a range
of insulin levels and insulin resistance in the Insulin Resistance and Atherosclerosis Study
(IRAS). These studies served both to confirm findings in the case-control study and to
provide the opportunity to investigate diverse populations. The collaboration with IRAS
allowed determination of the effects of insulin resistance and insulin secretory capacity on
TGRL size and number. Finally, experiments with cultured endothelial cells were performed to
determine if small TGRL could cause endothelial dysfunction. PMI-1 and VCAM-1 were markers
of TGRL effects. In the case-control study, plasma PMI and VCAM-1 were measured to examine
their relationship to coronary artery disease and to TGRL size and number.
Dollars awarded were estimated based on the CRISP assignment of $173,249 dollars in FY 1996
for Subproject 3. This was approximately 25 percent of the total dollars awarded and was
used to estimated committed dollars.
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|